Developer docs
API playgroundTry for free, no card

Search company profiles

AmacaThera

Full company profile

uuid0002atx

Namestring
AmacaThera
Legal namestring
AmacaThera Inc.
Websiteurl
amacathera.ca
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hydrogel drug delivery, sustained release therapeutics, non-opioid analgesic, pharmaceutical licensing platform, injectable biomaterials
Industry2 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Drug Delivery
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

AmacaThera generates revenue through exclusive global licensing agreements with pharmaceutical companies. The company receives upfront payments upon deal signing and additional milestone payments tied to clinical development, regulatory approvals, and commercialization achievements. The Pacira BioSciences agreement includes US$5 million upfront and up to US$225 million in future milestones.

prnewswire.co.uk
2Co-development Partnerships
TypeLicensing Royalties
Description

Collaborative partnerships where pharma partners fund clinical development activities, with AmacaThera providing its hydrogel platform technology and maintaining ownership of core IP while generating value through partnership structures.

prnewswire.co.uk
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AmacaThera develops and licenses a proprietary injectable hydrogel drug delivery platform (AmacaGel) that integrates hyaluronic acid and methylcellulose for precise, localized, and sustained therapeutic release. Its lead product, AMT-143, is a long-acting non-opioid local anesthetic for post-surgical pain that has completed Phase 1 trials and is being advanced via an exclusive global licensing deal with Pacira BioSciences. The company monetizes its platform by licensing to pharmaceutical partners rather than selling finished products directly.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Non-opioid alternative for post-surgical pain management reducing reliance on opioids
+2 more records
Product overview1 text field

AmacaThera is a clinical-stage biotechnology company offering a proprietary AmacaGel injectable hydrogel drug delivery platform. The platform enables precise, localized, and sustained delivery of therapeutics by integrating hyaluronic acid and methylcellulose. The company's lead product is AMT-143, a long-acting non-opioid analgesic for post-surgical pain, currently in Phase 2 preparation. The AmacaGel platform supports various therapeutic agents including small molecules, biologics, antibodies, peptides, nanoparticles, and cells, with applications spanning post-surgical pain management and oncology.

Product and service3 records
1AmacaGel Platform
CategoryDrug Delivery Platform
Description

Proprietary injectable hydrogel platform combining hyaluronic acid and methylcellulose for tunable, localized, sustained drug delivery. Compatible with small molecules, biologics, enzymes, antibodies, peptides, nanoparticles, and cells. Licensed to pharmaceutical partners for pipeline development across post-surgical pain, oncology, and other indications.

2AMT-143
CategoryTherapeutic Product Candidate
Description

Long-acting, non-opioid local anesthetic for post-surgical pain management built on the AmacaGel platform. Licensed exclusively to Pacira BioSciences globally; Pacira funds development, manufacturing, and commercialization. Phase 1 completed; Phase 2 planned for 2026.

3Pain (Post-Operative) Fixed Dose Product
CategoryTherapeutic Product Candidate
Description

Pre-filled syringe formulation of a local anesthetic using the AmacaGel hydrogel for sustained post-surgical pain relief. Represents a fixed-dose, ready-to-administer format of the platform's pain indication.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-04
Description

AmacaThera entered an exclusive global licensing agreement with Pacira BioSciences to develop and commercialize AMT-143, a long-acting non-opioid anesthetic for post-operative pain management. The agreement includes a US$5 million upfront payment and potential milestone payments up to US$225 million, validating AmacaThera's tunable hydrogel drug delivery platform. Pacira will fund clinical development, manufacturing, and commercialization, with Phase 2 trials expected to begin in 2026.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pacira is AmacaThera's exclusive global licensee for AMT-143 and a leader in non-opioid, long-acting injectable pain therapeutics (e.g., Exparel). It is directly comparable as a commercial-stage company operating in the same post-surgical pain market AMT-143 targets, and it provides a benchmark for the platform's commercial trajectory.

TypeDirect peer
Description

Halozyme's ENHANZE drug delivery platform licenses sub-Q delivery technology to major pharma partners (Roche, Pfizer, J&J, etc.) in a model structurally similar to AmacaThera's AmacaGel platform licensing approach. It is the most directly comparable business model in drug delivery platform licensing.

TypeDirect peer
Description

Heron develops long-acting, injectable post-surgical pain and oncology support products (e.g., Zynrelef, Sustol). It competes directly with AmacaThera in the post-operative non-opioid pain space and offers a useful commercial-stage benchmark for AMT-143's target indication.

4Innocoll Pharmaceuticals
TypeDirect peer
Description

Innocoll develops biodegradable, collagen-based drug delivery systems for localized and sustained therapeutic release. It is a direct peer in the polymer-based injectable drug delivery platform space and shares AmacaThera's emphasis on tunable, sustained-release formulations.

TypeEmerging player
Description

Enable Injections develops subcutaneous drug delivery systems (enFuse) that simplify large-volume, sustained delivery of biologics. It overlaps with AmacaThera's mission of improving patient experience through enhanced injectable delivery technologies, though focused on a different delivery modality.

TypeEmerging player
Description

InSitu Biologics develops an injectable, sustained-release drug delivery platform (Matrix-Q) targeting post-surgical pain and other localized indications. It overlaps directly with AmacaThera's mechanism and target indication, but is at an earlier commercial stage.

TypeOthers
Description

Crinetics is a clinical-stage biotech that has scaled a platform of peptide therapeutics through major partnerships. It is comparable to AmacaThera as a small-cap clinical-stage biotech leveraging external partnerships to advance proprietary technology platforms.

TypeOthers
Description

Aprea is a clinical-stage oncology biotech with a small team and partnered pipeline assets. It serves as a useful comparable for valuation benchmarking of small clinical-stage biotechs operating through partnership/licensing models similar to AmacaThera's.

TypeBroad incumbent
Description

Bausch Health develops sustained-release ocular drug delivery platforms through its Bausch + Lomb unit, including implants and injectable systems. It is a broad incumbent in sustained-release injectable therapeutics that operates across multiple therapeutic areas adjacent to AmacaThera's target spaces.

TypeBroad incumbent
Description

Indivior commercializes long-acting injectable therapies (e.g., Sublocade) for substance use disorders and is a broader incumbent in long-acting injectable drug delivery. It is comparable in its emphasis on long-acting injectable formulation and commercialization pathways relevant to AmacaThera's AMT-143.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AmacaThera

Biopharmaceutical Drug Deliveryamacathera.ca

AmacaThera firmographics

Firmographics
Name
AmacaThera
Legal name
AmacaThera Inc.
Website
https://amacathera.ca
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

AmacaThera industry classification

Industry
Product category
Biopharmaceutical Drug Delivery
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Hydrogel drug delivery
  • Sustained release therapeutics
  • Non-opioid analgesic
  • Pharmaceutical licensing platform
  • Injectable biomaterials

Where AmacaThera is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

AmacaThera business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

  1. Licensing and Milestone Payments: AmacaThera generates revenue through exclusive global licensing agreements with pharmaceutical companies. The company receives upfront payments upon deal signing and additional milestone payments tied to clinical development, regulatory approvals, and commercialization achievements. The Pacira BioSciences agreement includes US$5 million upfront and up to US$225 million in future milestones.
  2. Co-development Partnerships: Collaborative partnerships where pharma partners fund clinical development activities, with AmacaThera providing its hydrogel platform technology and maintaining ownership of core IP while generating value through partnership structures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

AmacaThera product offering

Product offering

Core offering

AmacaThera develops and licenses a proprietary injectable hydrogel drug delivery platform (AmacaGel) that integrates hyaluronic acid and methylcellulose for precise, localized, and sustained therapeutic release. Its lead product, AMT-143, is a long-acting non-opioid local anesthetic for post-surgical pain that has completed Phase 1 trials and is being advanced via an exclusive global licensing deal with Pacira BioSciences. The company monetizes its platform by licensing to pharmaceutical partners rather than selling finished products directly.

Product overview

AmacaThera is a clinical-stage biotechnology company offering a proprietary AmacaGel injectable hydrogel drug delivery platform. The platform enables precise, localized, and sustained delivery of therapeutics by integrating hyaluronic acid and methylcellulose. The company's lead product is AMT-143, a long-acting non-opioid analgesic for post-surgical pain, currently in Phase 2 preparation. The AmacaGel platform supports various therapeutic agents including small molecules, biologics, antibodies, peptides, nanoparticles, and cells, with applications spanning post-surgical pain management and oncology.

Differentiator

Problem solved

Functional benefit

Products and services

  • AmacaGel Platform Proprietary injectable hydrogel platform combining hyaluronic acid and methylcellulose for tunable, localized, sustained drug delivery. Compatible with small molecules, biologics, enzymes, antibodies, peptides, nanoparticles, and cells. Licensed to pharmaceutical partners for pipeline development across post-surgical pain, oncology, and other indications.
  • AMT-143 Long-acting, non-opioid local anesthetic for post-surgical pain management built on the AmacaGel platform. Licensed exclusively to Pacira BioSciences globally; Pacira funds development, manufacturing, and commercialization. Phase 1 completed; Phase 2 planned for 2026.
  • Pain (Post-Operative) Fixed Dose Product Pre-filled syringe formulation of a local anesthetic using the AmacaGel hydrogel for sustained post-surgical pain relief. Represents a fixed-dose, ready-to-administer format of the platform's pain indication.

Quantifiable outcome

  • Non-opioid alternative for post-surgical pain management reducing reliance on opioids
  • +2 more outcomes

Companies that use AmacaThera

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

AmacaThera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

AmacaThera partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Pacira BioSciencesflagshipOEM/ Whitelabel/ Licensing Partner · 4 November 2025AmacaThera entered an exclusive global licensing agreement with Pacira BioSciences to develop and commercialize AMT-143, a long-acting non-opioid anesthetic for post-operative pain management. The agreement includes a US$5 million upfront payment and potential milestone payments up to US$225 million, validating AmacaThera's tunable hydrogel drug delivery platform. Pacira will fund clinical development, manufacturing, and commercialization, with Phase 2 trials expected to begin in 2026.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

AmacaThera competitors and assessment

Company assessment

Direct peers

  • Pacira BioSciences: Pacira is AmacaThera's exclusive global licensee for AMT-143 and a leader in non-opioid, long-acting injectable pain therapeutics (e.g., Exparel). It is directly comparable as a commercial-stage company operating in the same post-surgical pain market AMT-143 targets, and it provides a benchmark for the platform's commercial trajectory.
  • Halozyme Therapeutics: Halozyme's ENHANZE drug delivery platform licenses sub-Q delivery technology to major pharma partners (Roche, Pfizer, J&J, etc.) in a model structurally similar to AmacaThera's AmacaGel platform licensing approach. It is the most directly comparable business model in drug delivery platform licensing.
  • Heron Therapeutics: Heron develops long-acting, injectable post-surgical pain and oncology support products (e.g., Zynrelef, Sustol). It competes directly with AmacaThera in the post-operative non-opioid pain space and offers a useful commercial-stage benchmark for AMT-143's target indication.
  • Innocoll Pharmaceuticals: Innocoll develops biodegradable, collagen-based drug delivery systems for localized and sustained therapeutic release. It is a direct peer in the polymer-based injectable drug delivery platform space and shares AmacaThera's emphasis on tunable, sustained-release formulations.

Emerging players

  • Enable Injections: Enable Injections develops subcutaneous drug delivery systems (enFuse) that simplify large-volume, sustained delivery of biologics. It overlaps with AmacaThera's mission of improving patient experience through enhanced injectable delivery technologies, though focused on a different delivery modality.
  • InSitu Biologics: InSitu Biologics develops an injectable, sustained-release drug delivery platform (Matrix-Q) targeting post-surgical pain and other localized indications. It overlaps directly with AmacaThera's mechanism and target indication, but is at an earlier commercial stage.

Others

  • Crinetics Pharmaceuticals: Crinetics is a clinical-stage biotech that has scaled a platform of peptide therapeutics through major partnerships. It is comparable to AmacaThera as a small-cap clinical-stage biotech leveraging external partnerships to advance proprietary technology platforms.
  • Aprea Therapeutics: Aprea is a clinical-stage oncology biotech with a small team and partnered pipeline assets. It serves as a useful comparable for valuation benchmarking of small clinical-stage biotechs operating through partnership/licensing models similar to AmacaThera's.

Broad incumbents

  • Bausch + Lomb (Bausch Health): Bausch Health develops sustained-release ocular drug delivery platforms through its Bausch + Lomb unit, including implants and injectable systems. It is a broad incumbent in sustained-release injectable therapeutics that operates across multiple therapeutic areas adjacent to AmacaThera's target spaces.
  • Indivior: Indivior commercializes long-acting injectable therapies (e.g., Sublocade) for substance use disorders and is a broader incumbent in long-acting injectable drug delivery. It is comparable in its emphasis on long-acting injectable formulation and commercialization pathways relevant to AmacaThera's AMT-143.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

AmacaThera social profiles

Digital presence

AmacaThera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AmacaThera leadership team

Management profile

Number of profiles

Profiles6 records

AmacaThera funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AmacaThera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AmacaThera

What does AmacaThera do?

AmacaThera develops and licenses a proprietary injectable hydrogel drug delivery platform (AmacaGel) that integrates hyaluronic acid and methylcellulose for precise, localized, and sustained therapeutic release. Its lead product, AMT-143, is a long-acting non-opioid local anesthetic for post-surgical pain that has completed Phase 1 trials and is being advanced via an exclusive global licensing deal with Pacira BioSciences. The company monetizes its platform by licensing to pharmaceutical partners rather than selling finished products directly.

Is AmacaThera a public or private company?

AmacaThera is a private company. It is classified as venture growth investor backed and is currently operating.

When was AmacaThera founded?

AmacaThera was founded in 2016. It employs 11 to 50 people.

Where is AmacaThera based?

AmacaThera is headquartered in Toronto, Canada, in the North America region.

How does AmacaThera make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are co-development Partnerships.

Who are AmacaThera's main competitors?

Direct peers on record are Pacira BioSciences, Halozyme Therapeutics, Heron Therapeutics and Innocoll Pharmaceuticals. Emerging players are Enable Injections and InSitu Biologics. Others are Crinetics Pharmaceuticals and Aprea Therapeutics. Broad incumbents are Bausch + Lomb (Bausch Health) and Indivior.

Does AmacaThera have an API?

No public API is recorded for AmacaThera.

What industry is AmacaThera in?

AmacaThera's product category is Biopharmaceutical Drug Delivery. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
UtorontoU of T Entrepreneurship Week: 10 startups to watch in 2026The University of Toronto is showcasing 10 affiliated startups during its ninth annual Entrepreneurship Week (March 2-6), highlighting ventures across sectors including space communications, AI, biotech, autonomous vehicles, and sustainable materials. Notable highlights include Waabi raising $1 billion for autonomous transportation, AmacaThera securing a $300 million licensing deal for a non-opioid anesthetic platform, and Kepler Communications operating Canada's largest fleet of domestically-built satellites. Cohere, an AI company co-founded by Geoffrey Hinton's former students, achieved a valuation exceeding $9.5 billion in its September 2025 funding round.Mirage NewsU of T Week: 10 Startups to Watch by 2026The University of Toronto is celebrating its ninth annual Entrepreneurship Week from March 2-7, profiling 10 affiliated startups across sectors including satellite communications, AI, biotech, autonomous vehicles, EV charging, aerospace, water purification, sustainable fashion, pharmacy technology, and enterprise AI. Featured companies have achieved notable milestones including Waabi's $1 billion fundraising round, AmacaThera's $300 million-plus licensing agreement for a non-opioid anesthetic platform, and Cohere's $9 billion valuation, while others like Kiwi Charge are piloting projects with major partners including General Motors Canada and Pfaff Automotive.PR NewswireAmacaThera Named Life Sciences Ontario Emerging Company of the YearAmacaThera, a developer of next-generation hydrogel-based drug delivery solutions, has been named Emerging Company of the Year by Life Sciences Ontario, recognizing its evolution from an early-stage biotech into a global innovator. The award highlights the company's recent momentum following an exclusive US$230 million global licensing agreement with Pacira BioSciences to advance AMT-143, an investigational long-acting, non-opioid anesthetic for post-operative pain management, with Phase 2 trials planned for 2026. The recognition validates AmacaThera's proprietary hydrogel platform, which enables precise, tunable, and sustained release of therapeutics and supports collaborations with multiple pharmaceutical partners.PharmiWeb.comAmacaThera Named Life Sciences Ontario Emerging Company of the YearAmacaThera, a developer of hydrogel-based drug delivery solutions, has been named Emerging Company of the Year by Life Sciences Ontario at its 23rd Annual Awards, recognizing the company's evolution from an early-stage biotech into a global innovator. The award comes amid significant momentum following AmacaThera's exclusive US$230 million global licensing agreement with Pacira BioSciences for its long-acting, opioid-sparing anesthetic AMT-143, with Phase 2 clinical trials prepared to begin in 2026. The recognition highlights AmacaThera's validated hydrogel platform technology, which enables precise, tunable, and sustained release of therapeutics across small molecules and biologics.PharmiWeb.comAmacaThera Named Life Sciences Ontario Emerging Company of the YearAmacaThera, a Toronto-based developer of hydrogel-based drug delivery solutions, has been named Life Sciences Ontario's Emerging Company of the Year, recognizing its evolution from an early-stage biotech into a global innovator.PR NewswireAmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery PlatformAmacaThera announced an exclusive worldwide licensing agreement with Pacira BioSciences for AMT-143, its long-acting non-opioid anesthetic for post-operative pain based on a tunable hydrogel platform that delivers sustained ropivacaine release for up to 14 days. Under the terms, AmacaThera will receive US$5 million upfront and up to US$225 million in development and sales-based milestone payments plus tiered royalties on net sales. The companies will collaborate on a Phase 2 clinical trial expected to begin in 2026, after which Pacira will assume full responsibility for development, manufacturing, and commercialization.GlobeNewswirePacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain ControlPacira BioSciences announced an exclusive worldwide license and collaboration agreement with AmacaThera for AMT-143, a novel long-acting formulation of the non-opioid analgesic ropivacaine for postsurgical pain control. Under the terms, Pacira will fund clinical development through commercial launch, with AmacaThera receiving a $5 million upfront payment plus potential development milestones and tiered royalties on future net sales. The companies expect to initiate a Phase 2 program in 2026, and the asset is described as aligning with Pacira's 5x30 growth strategy targeting clinical-stage, derisked opportunities with commercial synergies to its existing pain management portfolio.PR NewswireAmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery PlatformAmacaThera has signed an exclusive worldwide licensing agreement with Pacira BioSciences for AMT-143, a long-acting non-opioid anesthetic leveraging AmacaThera's tunable hydrogel platform for sustained ropivacaine release of up to 14 days. Under the deal, AmacaThera receives US$5 million upfront and up to US$225 million in future development and sales-based milestone payments plus tiered royalties on net sales. Pacira will fund and assume responsibility for clinical development through commercialization, with a Phase 2 trial expected to commence in 2026, representing major validation of AmacaThera's drug delivery technology.